Nektar Corp (NKTR): Analyst Consensus Forecast
This chart of Nektar Therapeutics (NKTR) share prices reflects the dynamics of a company developing innovative methods to combat oncology and autoimmune pathologies for the B2B segment, where the indicator stands at 133.50. The business operates in a non-cyclical sector, relying on clinical trial results and partnerships with major corporations. Development stability is maintained by retaining a staff of leading biochemists and the strategic hiring of specialists.
Analytical breakdowns for Nektar (NKTR)
- stock price and consensus target price:
- stock exchange capitalization data:
- balance sheet equity data:
- business debt structure and liquidity details:
Aggregate Debt to Equity Nektar Therapeutics|NKTR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Nektar Corp|NKTR - Company Aggregate Debts|Debts to Book Capitalization Nektar|NKTR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Nektar Therapeutics|Quick Liquidity Indicator nektar.com
- earnings and market ratios statistics:
NKTR - Net Profit|Projected Future Earnings Nektar Therapeutics|NKTR - Price to Earnings Ratio|Future Price to Earnings Multiple Nektar Therapeutics Inc|NKTR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Nektar|NKTR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Nektar Therapeutics|NKTR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months nektar.com|NKTR - Net earnings per share growth this year|Earnings growth forecast for next year Nektar Therapeutics
General company analysis:NKTR nektar.com
The stability of Nektar Therapeutics (NKTR) immunological developments within Western legal frameworks minimizes geopolitical risks. This metric aggregates fragmented investment bank forecasts into a single data set, reflecting the asset's average fundamental value. Daily recalculations enable the timely detection of deviations between the market price and the objective valuation. This protects capital from the purchase of overvalued securities. The price action of the analysts' target price indicator serves as a filter for making informed decisions.
Competitors of Nektar Therapeutics
argenx.com - Broker Consensus Forecast|Price Target Chart BioNTech BNTX|Analyst Consensus Forecast Abivax SA ABVX|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|Immunovant, Inc. (IMVT) - Price Target Chart|kiniksa.com - Fair Value Consensus|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target UPB (Upstream Bio)|ZBIO (Zenas Bio) - Fair Value Consensus|Analyst Consensus Forecast IMNM (Immunome Corp)|Analyst Median Target Gossamer Bio Corp. (GOSS)|KALV - Price Target Chart|septerna.com (SEPN) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS - Price Target Chart|KYTX (Kyverna Therapeutics, Inc) - Broker Consensus Forecast|TLSA: Analyst Consensus Forecast|Average Forecast Price cabalettabio.com (CABA)|Price Target Chart Ventyx Biosciences, Inc.|Analyst Consensus Forecast Theratechnologies, Inc.|Consensus Target AVTX (Avalo Therapeutics Inc.)|Analyst Forecast Prices ELDN|Analyst Consensus Forecast AGEN (Agenus)|Analyst Consensus Forecast climbbio.com CLYM|ZURA - Price Target Chart|Fair Value Consensus ATYR (aTyr Pharma Inc)|ADAG (adagene.com) - Consensus Target|Ikena Oncology - Fair Value Consensus|Consensus Target STTK|EQ (Equillium Bio) - Analyst Forecast Prices|Analyst Consensus Forecast CNTB|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast ATRA (Atara Bio)|InflaRx NV (IFRX) - Average Forecast Price|XFOR - Price Target Chart|Fair Value Consensus ACET (Adicet Bio)|CELU: Analyst Consensus Forecast|INmune Bio Inc (INMB) - Analyst Consensus Forecast|Price Target Chart Barinthus Bio|Kezar Life Sciences Inc - Forecast Levels Chart|Analyst Consensus Forecast SABS|AKTX - Average Forecast Price|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Consensus Forecast Q32 Bio Inc QTTB|GOVX: Consensus Target|Edesa Biotech Corp - Analyst Forecast Prices|IBIO: Analyst Consensus Forecast|CARM - Analyst Median Target|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Consensus Target Bolt Bio (BOLT)|Price Target Chart HCW Biologics Inc. (HCWB)|Analyst Median Target aptevotherapeutics.com|Price Target Chart AIM ImmunoTech AIM|ADTX: Broker Consensus Forecast|GRI - Price Target Chart|XRTX - Analyst Consensus Forecast|HIND (ReShape Lifesciences) - Consensus Target|REVB: Analyst Forecast Prices|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Price Target Chart CalciMedica, Inc. (CALI)|AFMD: Forecast Levels Chart|Analyst Consensus Forecast ALLK (Allakos)|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|TC BioPharm (Holdings) Plc - Fair Value Consensus|Price Target Chart Third Harmonic Bio, Inc
